The German Breast Group conducts research into breast cancer, developing and implementing its own study concepts.
With the help of additional scientific research projects, we strive to gain further insights into this disease.
Auf dem ASCO-Kongress 2019 konnten wir einige Ergebnisse und neue Studienkonzepte der GBG vorestellen.
Results of a next-generation sequencing (NGS) analysis conducted in the neoadjuvant GeparSepto study (GBG 69) have been published in the Clinical Cancer Research.
The initial results of AURORA were announced at the ESMO Breast Cancer Congress in Berlin.
Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.
We are pleased to inform you that the results of the E-VITA study that evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER2-positive metastatic breast cancer have been published in the Anticancer Drugs.
Every month, we present an interesting paper.
We are delighted to inform you that our analysis on the utility of the CPS + EG score in triple-negative breast cancer patients has been published in European Journal of Cancer